GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OHEL:BONEH) » Definitions » Capex-to-Operating-Income

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

BBS-Bioactive Bone Substitutes's Capital Expenditure for the six months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-1.79 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


BBS-Bioactive Bone Substitutes Capex-to-Operating-Income Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes Capex-to-Operating-Income Chart

BBS-Bioactive Bone Substitutes Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - -

BBS-Bioactive Bone Substitutes Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income

For the Medical Devices subindustry, BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income falls into.



BBS-Bioactive Bone Substitutes Capex-to-Operating-Income Calculation

BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.367
=N/A

BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.793
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BBS-Bioactive Bone Substitutes  (OHEL:BONEH) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


BBS-Bioactive Bone Substitutes Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BBS-Bioactive Bone Substitutes (OHEL:BONEH) Business Description

Traded in Other Exchanges
N/A
Address
Kiviharjunlenkki 6, Oulu, FIN, 90220
BBS-Bioactive Bone Substitutes PLC is a health technology company, that develops, designs, and manufactures bioactive bone-graft substitute implants. Its ortho-biological product ARTEBONE, which is based on tricalcium phosphate and a natural spectrum of bone proteins has the capability of bone regeneration.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Headlines

No Headlines